Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ReShape Lifesciences Inc (RSLS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RSLS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -26.55% | Avg. Invested days 69 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.64M USD | Price to earnings Ratio 0.07 | 1Y Target Price 1 |
Price to earnings Ratio 0.07 | 1Y Target Price 1 | ||
Volume (30-day avg) 10455916 | Beta 1.35 | 52 Weeks Range 0.34 - 16.59 | Updated Date 03/30/2025 |
52 Weeks Range 0.34 - 16.59 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 76.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -112.11% | Operating Margin (TTM) -104.53% |
Management Effectiveness
Return on Assets (TTM) -63.46% | Return on Equity (TTM) -184.59% |
Valuation
Trailing PE 0.07 | Forward PE - | Enterprise Value 639483 | Price to Sales(TTM) 0.64 |
Enterprise Value 639483 | Price to Sales(TTM) 0.64 | ||
Enterprise Value to Revenue 0.08 | Enterprise Value to EBITDA -0.02 | Shares Outstanding 712680 | Shares Floating 466552 |
Shares Outstanding 712680 | Shares Floating 466552 | ||
Percent Insiders 5.58 | Percent Institutions 1.83 |
Analyst Ratings
Rating 3 | Target Price 1 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ReShape Lifesciences Inc
Company Overview
History and Background
ReShape Lifesciences Inc. is a medical device company focused on developing and commercializing innovative solutions for obesity and metabolic diseases. Founded in 2002 as EnteroMedics, they initially focused on vagal nerve blocking technology. After facing challenges with the VBLOC device, the company shifted its focus to less invasive solutions, eventually becoming ReShape Lifesciences.
Core Business Areas
- ReshapeCare Virtual Health Program: A telehealth program providing comprehensive support for weight loss patients, including coaching, nutrition plans, and exercise guidance.
- Lap-Band Program: A minimally invasive surgical procedure involving the placement of an adjustable gastric band around the upper stomach to restrict food intake.
Leadership and Structure
The leadership team consists of Paul Hickey (President and CEO). The organizational structure follows a typical corporate hierarchy with departments for R&D, sales, marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- ReshapeCare Virtual Health Program: Provides personalized support and guidance for weight management. Market share data is difficult to pinpoint as telehealth weight loss programs are increasingly prevalent. Competitors include WW International, Noom, Calibrate, and Found.
- Lap-Band Program: A surgical weight loss procedure. Lap-Band procedures face competition from other bariatric surgeries like gastric bypass and sleeve gastrectomy. Market share data is fragmented and varies by region. Competitors include Apollo Endosurgery, Intuitive Surgical, and Medtronic (for related surgical technologies).
Market Dynamics
Industry Overview
The weight loss and obesity management market is growing due to rising obesity rates and increasing awareness of associated health risks. The market includes surgical procedures, medical devices, pharmaceuticals, diet programs, and telehealth services.
Positioning
ReShape Lifesciences aims to position itself as a provider of less invasive and more comprehensive weight loss solutions compared to traditional bariatric surgery. Their competitive advantage lies in offering a combination of surgical and non-surgical options alongside a virtual health program.
Total Addressable Market (TAM)
The global weight management market is estimated to be in the billions of dollars annually. ReShape Lifesciences is positioned to capture a share of this TAM through its virtual health program and surgical options.
Upturn SWOT Analysis
Strengths
- Comprehensive weight loss solutions (surgical and non-surgical)
- Virtual health program (ReshapeCare)
- Focus on less invasive procedures
- Established brand name in Lap-Band market
Weaknesses
- Small market capitalization
- History of losses
- Reliance on Lap-Band, which has declining popularity
- Intense competition
Opportunities
- Expanding the ReshapeCare virtual health program
- Developing new weight loss devices
- Partnerships with healthcare providers
- Growing awareness of obesity and metabolic diseases
Threats
- Competition from established weight loss companies
- Regulatory changes
- Economic downturn
- Negative publicity surrounding bariatric surgery
Competitors and Market Share
Key Competitors
- WW (WW)
- Noom (Privately Held)
- Medtronic (MDT)
- Intuitive Surgical (ISRG)
- Apollo Endosurgery (APEN)
Competitive Landscape
ReShape Lifesciences faces competition from established weight loss companies with larger market shares and more resources. Their advantage lies in their comprehensive solutions and focus on less invasive procedures, but they must effectively market and execute their strategy to gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent due to challenges with the Lap-Band and a shift in focus towards virtual health solutions.
Future Projections: Future growth is dependent on the success of the ReshapeCare program and the development of new products. Analyst estimates are highly variable.
Recent Initiatives: Recent initiatives include expanding the ReshapeCare program and exploring new partnerships.
Summary
ReShape Lifesciences is a small medical device company with a focus on weight loss solutions. Its strength lies in its comprehensive approach with both surgical and non-surgical options, but its weaknesses include a small market cap and past financial losses. The company's future depends on the success of its ReshapeCare virtual health program and its ability to compete with larger, more established players. The success is tied to the market's adoption of the Lap-Band and its non-surgical weight loss programs.
Similar Companies
ISRG
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
MDT
Medtronic PLC
MDT
Medtronic PLC
WW
WW International Inc
WW
WW International Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Yahoo Finance
- Google Finance
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Consult with a qualified financial advisor before making any investment decisions. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ReShape Lifesciences Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2007-11-15 | CEO, President & Director Mr. Paul F. Hickey | ||
Sector Healthcare | Industry Medical Devices | Full time employees 29 | |
Full time employees 29 | |||
ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.